The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements. No surprise, there’s a lot about the genetically engineered cell therapy known as CAR-T.... Read more »
As a tech startup that uses an algorithm to help people find out what song is playing on the radio, Shazam is a business its co-founders say was ahead of its time in 2000—so much so that they developed the technology... Read more »
Light Detection and Ranging (LiDAR) is one of the most important technologies underpinning the development of driverless cars. LiDAR systems feed raw sensor data to the car’s brain, creating a 3D picture of the surrounding environment and enabling autonomous vehicles to... Read more »
When Alex Niehenke started his business career at an investment bank in 2005 as an advisor to Internet companies, there was one strongly held consensus among investors.
“You just didn’t touch regulated industries,” says Niehenke, who was recently promoted to partner... Read more »
Whether you think self-driving cars are the stuff of science fiction or a potentially paradigm-shifting new form of transportation, autonomous vehicles are coming—and the companies developing them are spending big money to make it happen.
A few years ago, industry analysts... Read more »
Denali Therapeutics has raised more than $248 million in its stock market debut, marking the largest biotech IPO of the year. The company will use the cash to support work on its experimental drugs for Parkinson’s disease and other neurodegenerative disorders.... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
Gilead Sciences is deepening its capabilities in cell therapy with a deal valued at up to $567 million to acquire Cell Design Labs, a company that discovers and develops such treatments.
The announcement late Thursday comes a little more than four... Read more »
Rahul Chaturvedi worked for 16 years as a life sciences company executive, but he was also an avid consumer tech fan who chafed at the clunky enterprise apps used in his industry. Spoiled by speedy, user-friendly consumer apps, he also wondered... Read more »
Healthcare investment giant OrbiMed Advisors has been described as a workplace enveloped in a toxic culture of sexual harassment, according to an investigation by Stat released late Tuesday.
OrbiMed managing partner and co-founder Samuel Isaly is the main perpetrator of frequent... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
[Corrected, 12/11/17, 1 p.m. ET. See below.] On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease,... Read more »
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing.
As remarkable as they might seem, however, these medicines... Read more »